Clinical Trial

Preemptive Analgesia Of Dexmedetomidine Reduces Per-operation Pain

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 9, 2025 (before its estimated June 23, 2025 completion). Its status may not reflect the trial's current state.
Summary
Background:Preemptive analgesia is the initiation of analgesic regimen before the onset of nociceptive stimulation, preventing the amplification of pain due to peripheral and central sensitization and thereby reducing subsequent pain. Preemptive analgesia of dexmedetomidine (DEX) in the epidural and subarachnoid space can effectively prevent the central sensitization, and significantly reduce the phantom limb pain, residual pain after one year of lower limb amputation. Objective: To investigate the per-operative effects of DEX preemptive analgesia. Method:The patients scheduled noncardiac surgery undergoing general anesthesia were selected and divided into DEX group and Placebo group randmized. The DEX group was continuously pumped at 1.5 μg /(kg·h) for 15 minutes before induction, and 15min after induction. The Placebo group was infused with equal amounts of normal saline.The Coprimary efficacy outcome was a composite of analgesia effect, one is the Compliance Rate of IOC2 target in intra-operation, another is the the rate of none-to-slight post-operative pain assessed with the p-NRS≦3 at 12 hours after surgery \[Pain numeric rating scale was assessed with the (Numeric Rating Scale, p-NRS)\].
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-31.
Trial Details
NCT Number NCT06671327
Lead Sponsor China International Neuroscience Institution
Conditions Pain Management, Noncardiac Surgery
Enrollment 208 participants
Start Date 2025-04-03
Primary Completion 2025-06-23 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-09